Bifogade filer
Mendus (Q3 review) - Executing on updated clinical strategy
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från Redeye via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
2025-11-13 18:27:00
Redeye provides its comment on Mendus’ Q3 2025 report. We believe several upcoming clinical readouts in 2026e could spark partner interest and reinvigorate sentiment around the share. We believe Mendus will likely need to secure continued financing until our projected licensing deal in late 2026e.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/